Clinical Trials Browser

Leukemia, B-Cell

NCT04090268 2024-01-02

SportTherapy

Adrenoleukodystrophy, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Motor Activity, Neoplasms, Sickle Cell Trait, Leukemia, B-Cell, Leukemia, T-Cell, Leukemia, Myeloid, Acute, beta-Thalassemia

NCT03614858 2023-11-29

CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.

Phase 1/2 Unknown

20 enrolled

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT05350826 2023-09-21

THEMIS

Phase NA Unknown

450 enrolled

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT05932173 2023-07-11

A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies

Phase 1/2 Unknown

60 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, B-Cell, Lymphoma, B-Cell

NCT04763083 2023-07-07

First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

Phase 1 Unknown

90 enrolled

DermatologicLymphoidOther hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Follicular, Melanoma, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05487651 2023-05-18

ANCHOR2

Phase 1 Unknown

36 enrolled

LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Clinical Trials

INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia

SportTherapy

CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.

THEMIS

A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies

First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

ANCHOR2

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

CAR-T Cells in the Treatment of Malignant Hematological Tumors

PLANET

Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Induced-T Cell Like NK Cells for B Cell Malignancies

OFICE

γδT

Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia

The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients

A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia

Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?

A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma

A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia

A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

CAR T Cells for Refractory B Cell Malignancy

A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia

Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies

A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia

CLARITY

RIAltO